YAFO CAPITAL Grows Life Science Team and Launches China Out-Licensing Division

YAFO Capital, a Shanghai-based boutique investment & advisory firm focused on helping leading U.S. and European biopharma and MedTech companies successfully enter the Asian market, is pleased to announce the recent expansion of its life science team and the launching of China out-licensing division. 

With the growing China biopharma innovation in terms of both increasing number of innovative assets entering clinical trials and getting approved and increasing number of cross border out-licensing deals, we are excited about the joining of Kevin Wang to initiate and lead YAFO’s out-licensing division. 

Kevin Wang joining YAFO as Partner leading M&A and Out-Licensing Division

Mr. Wang has rich experience in pharma Business Development for more than 20 years with a record of more than 50 M&A and licensing transactions. He has worked in Saiya Consulting, Eisai Pharma, Leo Pharma, and Yiteng Pharma. He served as the head of the BD department at Hemony Pharmaceuticals. He has accumulated a wealth of theoretical knowledge and practical experience in BD strategy, project commercial launching, project negotiations, investment and M&As, and alliance management. Mr. Wang received his MBA at Manchester University in the UK and his bachelor at Hunan Medical University.

Andy Sun joining YAFO as Partner of pharma In-Licensing Division

Mr. Andy Sun has nearly twenty years of career experience in both the life science industry & banking sector. Before he joined YAFO Capital as Partner with the focus on cross border transactions, he is Investment Director at JFHR Investment Management Co., Ltd. Before that, Andy was Business Development Director at a Nasdaq listed company named CASI Pharmaceuticals Inc. focusing on in/out licensing deals He was a Product Manager at Tianjin Chase-sun Pharmaceuticals before working at CASI. His first job was Credit Analyst at ICBC, the largest commercial bank in China. Mr. Andy Sun received his bachelor's degree in Biochemical Engineering at Tianjin University. He received his M.SC of Biomedical Engineering at Luebeck University of Applied Sciences in Germany. 

William Yao joined YAFO as Partner leading MedTech Partnering & Investment Division

Mr. Yao has more than 30 years in the pharmaceutical and MedTech industry. Before joining YAFO Capital, he worked 7 years (1993-2000) in Astra China, the predecessor of AstraZeneca China, and oversaw government affairs, marketing, and BD in China. Also, he co-established the Cyberpharm Investment and Sino-Octa Holdings, focusing on the medical care field in China. He was responsible for the Sales and Marketing and BD in the company. Mr. Yao practiced two years as an OB doctor after graduation from the Medical College of Shanghai JiaoTong University in 1990. 

YAFO Life Science 

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and MedTech companies successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, investment & parternering target screening , and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. 

About YAFO Capital 

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment & advisory firm starting from bringing Israeli MedTech to China, now with a team of 20+ professionals in our China, U.S., Japan, and London offices. For more information on YAFO, please visit www.yafocapital.com


ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders with China, by directly meeting with the right partners for licensing, commercial collaborations, or investment. ONLINE ACCESS CHINA program offers participants opportunities to expand the exposure to much broader Chinese audience beyond the physical forums.


Qi Li

BD Director